The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro- 2-hydroxypropyl] -4,5-dihydro- 1H-1,2,4-triazol-1-yl Jmethyl)-1- [3-(trifluoromethyl)-pyridin-2-yl] - 1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2- hydroxypropyl] -4,5-dihydro- 1H-1,2,4-triazol-1-yl} methyl)-1- [2-(trifluoromethyl)-phenyl] -1H- 1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2- hydroxypropyl] -4,5-dihydro-1H-1,2,4-triazol-1-yl} methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4- triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
